Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I Study of FOR46 Administered Every 21 Days in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)

Trial Profile

A Phase I Study of FOR46 Administered Every 21 Days in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)

Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 06 Nov 2018

At a glance

  • Drugs FOR-46 (Primary)
  • Indications Multiple myeloma
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Fortis Therapeutics
  • Most Recent Events

    • 06 Nov 2018 According to a COI Pharmaceuticals media release, the U.S. Food and Drug Administration (FDA) has cleared investigational new drug (IND) application for FOR46 for the treatment of late-stage multiple myeloma
    • 04 Sep 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top